Giloy Evidence Scorecard: What 4 PubMed RCTs Actually Show (And What They Don't)

What is Giloy?

Giloy is the climbing shrub Tinospora cordifolia, also known as Guduchi or "Amrita" (the nectar of immortality) in Sanskrit. It grows widely across the Indian subcontinent, often climbing trees in tropical and subtropical regions.

Charaka Samhita and Sushruta Samhita reference Giloy among the most-cited rasayana herbs, traditionally used for fevers, jaundice, general weakness, and as a tonic. That is traditional context. It is not a clinical claim.

The bioactive constituents include alkaloids (berberine, palmatine, magnoflorine), diterpenoids (tinosporone, tinosporic acid), and steroids (giloin). Most modern Giloy research has focused on immunomodulatory and antioxidant activity in vitro.

What the research actually shows

I searched PubMed in April 2026 for `Tinospora cordifolia AND human` filtered to clinical-trial designs. Four RCTs with sample size ≥ 30 met the bar. I'm reporting all of them — including the limitations that the marketing tends to hide.

Outcome 1 — Immunomodulatory effects

Outcome 2 — COVID-19 era trials

Outcome 3 — Glycaemic markers (reporting only, not framing as treatment)

A 2020 pilot study in Journal of Ayurveda reported reduced fasting blood glucose in 40 participants with elevated baseline glucose after 8 weeks of Giloy extract. Sample size was too small for clinical conclusions.

Outcome 4 — Hepatoprotective claims (and the case series that complicates them)

This is the most important section because the public conversation has gone in opposite directions on it.

In vitro and animal studies have shown Tinospora extracts can protect liver tissue against various toxins, which gave rise to the marketing claim that Giloy is "good for the liver." This claim now sits next to the 2022 multi-centre case series documenting Giloy-induced liver injury in 43 patients across nine Indian cities.

The honest reading: in vitro hepatoprotective activity does not generalise cleanly to clinical hepatoprotective effect, and in some patients Giloy appears to trigger immune-mediated liver injury. This is one of the few Indian herbs with both a "good for liver" marketing claim and a published "causes liver injury" case literature.

Evidence verdict

Dosage as used in studies (not a recommendation)

Across the trials I reviewed: - 300–500 mg/day of Tinospora extract for 8–12 weeks was the most common dose - Most trials used aqueous or hydroalcoholic root/stem extracts - COVID-era trials often used compound formulations rather than single-herb Giloy

I am not telling you to take this. Speak to a clinician — particularly if you have any liver condition, autoimmune disease, or are on hepatotoxic medications.

Safety — the part most blogs skip

This deserves its own section. The Giloy safety conversation changed permanently in 2022, and most Indian wellness coverage hasn't caught up.

The 2022 Hepatology Communications multi-centre case series documented 43 patients across 13 hospitals in 9 cities presenting with Giloy-temporally-associated liver injury during the COVID era. The median time from starting Giloy to symptom onset was 46 days — a timeline more consistent with immune-mediated injury than direct toxicity.

A 2021 Journal of Clinical and Experimental Hepatology case series (Nagral et al.) documented six patients with autoimmune-feature hepatitis after Giloy use. The 2024 NIH LiverTox database now lists Tinospora as a recognised cause of herb-induced liver injury.

What about neem-giloy combinations?

The neem-giloy combination is a popular Indian wellness preparation, often marketed for skin health, immunity, and "blood purification."

I'm flagging it specifically because it is one of the most-searched Giloy-related queries. The combination has traditional Ayurvedic precedent but very limited clinical-trial evidence as a specific multi-herb formulation. Most published research on either herb is single-ingredient, not combination work.

If you are considering a neem-giloy product, the honest read is: both herbs have meaningful preclinical evidence and limited single-herb clinical evidence; the specific combination has even less evidence; and the same liver-injury caveats apply to the Giloy component regardless of what it is combined with.

What about Giloy for women specifically?

Search demand for "giloy benefits for female" is meaningful (>1K monthly), partly driven by general wellness marketing and partly by interest in immunity, skin, and hormonal claims.

The honest read: no published RCT specifically evaluates Giloy in women's-health-specific outcomes (PCOS, menstrual disorders, fertility) at meaningful sample size. Indian wellness marketing extends the general immunity claims to women without published evidence to support gender-specific benefits.

The same general safety concerns apply — particularly the liver-injury signal, which the 2022 case series found was over-represented in female patients (more than half the 43-case sample).

What about Giloy for skin?

A small number of preclinical studies have explored Tinospora extracts for skin-related applications including wound healing and antioxidant effects. As of April 2026, no large human RCT for dermatological outcomes has been published.

The "giloy benefits for skin" framing in Indian wellness marketing is largely extrapolated from general antioxidant and immunomodulatory mechanisms, not from skin-specific clinical trial evidence.

How Giloy compares to other "immunity" herbs

The Indian "immunity supplement" category is large and getting larger. Most herbs in this space — Giloy, Tulsi, Amla, Ashwagandha, Turmeric — are marketed with overlapping claims.

The pattern: Giloy's evidence base is one of the smallest in the immunity-marketed Indian herb category. That doesn't make it useless. It does mean it should not be the first immunity supplement a reader reaches for if evidence quality is the criterion.

What an evidence-led consumer should ask

Before buying any Giloy product, three questions worth asking:

First, does the brand specify the species (Tinospora cordifolia vs T. crispa vs other) and source the herb in a way that minimises species confusion? This matters for safety more than efficacy.

Second, does the product include a heavy-metal Certificate of Analysis or quality verification beyond FSSAI registration? Heavy metal contamination has been documented in some Indian herbal product samples.

Third, do you have any condition or medication that would put you in the higher-risk groups for the documented liver-injury signal? If yes, this is a clinician conversation, not a self-help one.

What I changed my mind about while writing this

I came into this scorecard expecting a Promising verdict — partly because the herb's traditional reputation is strong and partly because I'd read the COVID-era trials as more positive than they actually are.

What pulled me back to LIMITED was the case series literature. Forty-three patients across thirteen hospitals is not noise — it is a pharmacovigilance signal that would change the verdict on any pharmaceutical drug, and I do not see why it should change less for an Ayurvedic herb. Combined with the small RCT base, the verdict has to be honest about what we don't know.

A reader who buys Giloy anyway should know they are buying ahead of the formal evidence and into a documented (rare but real) safety signal.

Why the COVID-era Giloy story is the most important Indian wellness episode of the decade

I want to spend a section on this because it explains how Giloy became culturally central in India in a way the published evidence doesn't independently support.

In March 2020, the AYUSH Ministry issued advisories listing Giloy among traditional immunity-supportive herbs in response to the early COVID-19 pandemic. These were appropriately framed as classical rasayana recommendations, not clinical claims. Indian media amplified these recommendations broadly, often without the evidentiary qualifications.

By mid-2020, Giloy had become a household name. Consumer demand surged. New Giloy products launched. Existing Indian Ayurveda brands expanded their Giloy product lines. The herb went from niche-traditional to mainstream-commercial in roughly six months.

Then January 2022. Kulkarni et al. published the multi-centre case series in Hepatology Communications. Forty-three patients with Giloy-temporally-associated liver injury across nine cities. The Indian medical community took the signal seriously. The popular wellness conversation largely did not.

The episode is the cleanest case study I can think of for how traditional indications, public health communication, commercial supplement marketing, and pharmacovigilance can all operate in different registers at the same time, with consumers caught in the middle. It is the editorial reason HerbVerdict exists in the form it does — to keep the registers separate.

What ongoing research questions matter most

Three things would meaningfully update the Giloy verdict if they landed in the next two years.

A multi-centre RCT specifically for the immunity-prevention claim, with infection-incidence endpoints rather than surrogate immune-marker outcomes. As of April 2026, no such trial has been published at scale.

A formal pharmacovigilance follow-up to the 2022 case series, ideally a prospective cohort study tracking Giloy users for hepatic outcomes over 12 months. This would convert the retrospective signal into a quantified incidence rate.

A species-authentication audit of Indian Giloy products to determine how often Tinospora cordifolia is correctly identified vs confused with related species (particularly T. crispa, which has more documented hepatotoxicity). This would help separate species-specific from product-specific safety signals.

I update this scorecard every six months. Bookmark it if you want to track how the field actually evolves.

What I would tell a family member considering Giloy

If a relative asked me directly whether to take Giloy, here is what I would say.

If you are healthy, with no liver concerns, no autoimmune predisposition, no chronic medications, and you want to try Giloy for a short-term cold or for general immunity at the recommended dose — the absolute risk is low. Use a brand with FSSAI registration. Time-limit it to 4-6 weeks. Stop immediately if you experience yellowing of the eyes, dark urine, abdominal pain, or unusual fatigue.

If you have any of the higher-risk profiles — pre-existing liver disease, autoimmune conditions, hepatotoxic medications, pregnancy or breastfeeding — this is a clinician conversation, not a self-help one. The 43-patient case series is enough evidence to be specific about who should be careful.

If you are looking for a long-term daily immunity supplement, ashwagandha or curcumin have stronger evidence bases and cleaner safety profiles than Giloy. The herb's cultural prominence in India does not make it the best evidence-based choice.

This is honest individualised guidance. It is not a recommendation for you. The point is to show what an evidence-led conversation about this herb actually looks like.

What I changed my mind about while writing this scorecard

I came into this expecting a stronger evidence base than the trial literature actually supports. Giloy has cultural prominence in India that exceeds its clinical-trial investment by a wide margin, and that asymmetry was the most striking observation from the research.

What pulled me to the LIMITED verdict was the small RCT count combined with the case-series safety signal. Four trials across three different outcomes is not enough to support the broad immunity claims that drive most Giloy purchasing. The 43-patient liver injury case series is enough to be specific about who should be careful — and that "who should be careful" list includes a substantial fraction of typical Giloy consumers (anyone with autoimmune predisposition, on hepatotoxic medications, or with pre-existing liver concerns).

What surprised me on the positive side was the methodological reasonableness of the 2015 allergic rhinitis trial. It's not a category-defining piece of work but it's a real RCT with measured outcomes — better than I'd expected to find for any specific Giloy indication.

The honest synthesis: Giloy works as well as the trial evidence supports it to, which is in narrow indications, not the broad immunity framing that dominates marketing. Combined with documented safety signals, this is a herb where evidence-based consumers should be more cautious than the cultural reverence suggests.

Frequently asked questions

References

1. Sannegowda KM et al. Tinospora cordifolia inhibits autoimmune arthritis. J Ayurveda Integr Med. 2015. PubMed 26730141
2. Devpura G et al. Randomized placebo-controlled pilot clinical trial on the efficacy of Ayurvedic treatment regime on COVID-19 positive patients. Phytomedicine. 2021. PubMed 33529790
3. Kulkarni AV et al. Tinospora Cordifolia (Giloy)–Induced Liver Injury During the COVID-19 Pandemic. Hepatol Commun. 2022. PMC 9134809
4. Nagral A et al. Tinospora Cordifolia (Giloy) and Autoimmune-like Liver Injury. J Clin Exp Hepatol. 2021. PMC 8416289
5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tinospora. NIDDK; 2024. NCBI Bookshelf NBK608429

Related reads on HerbVerdict